We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Compass Pathways (CMPS) ADS

Sell:$4.45 Buy:$4.46 Change: $0.19 (3.97%)
NASDAQ:0.03%
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$4.45
Buy:$4.46
Change: $0.19 (3.97%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$4.45
Buy:$4.46
Change: $0.19 (3.97%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Contact details

Address:
3Rd Floor, 1 Ashley Road
ALTRINCHAM
WA14 2DT
United Kingdom
Telephone:
+44 (1646) 9053974
Website:
https://compasspathways.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CMPS
ISIN:
US20451W1018
Market cap:
$318.84 million
Shares in issue:
114.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kabir Nath
    Chief Executive Officer, Executive Director
  • Teri Loxam
    Chief Financial Officer
  • Matthew Owens
    General Counsel, Chief Legal Officer
  • Lori Englebert
    Chief Commercial Officer
  • Michael Gold
    Chief Research and Development Officer
  • Guy Goodwin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.